
Ask a doctor about a prescription for ZEDILARF 5 mg FILM-COATED TABLETS
Patient Information: Summary of Product Characteristics
Zedilarf 5mg film-coated tablets EFG
Zedilarf 10mg film-coated tablets EFG
dapagliflozin
Read the entire summary of product characteristics carefully before starting to take this medication, as it contains important information for you.
Contents of the Summary
What is Zedilarf
Zedilarf contains the active substance dapagliflozin. It belongs to a group of medications called "sodium-glucose cotransporter 2 (SGLT2) inhibitors". They work by blocking the SGLT2 protein in the kidney. By blocking this protein, sugar in the blood (glucose), salt (sodium), and water are eliminated from the body through urine.
What is Zedilarf used for
This medication is used to treat:
What is type 2 diabetes and how does Zedilarf help?
What is heart failure and how does Zedilarf help?
What is chronic kidney disease and how does Zedilarf help?
Do not take Zedilarf
Warnings and precautions
Contact a doctor or the nearest hospital immediately
Diabetic ketoacidosis:
If you suspect you have diabetic ketoacidosis, contact a doctor or the nearest hospital immediately and do not take this medication.
Necrotizing fasciitis of the perineum:
Consult your doctor, pharmacist, or nurse before starting to take this medication
If any of the above situations apply to you (or you are unsure), consult your doctor, pharmacist, or nurse before taking dapagliflozin.
Diabetes and foot care
If you have diabetes, it is essential that you regularly monitor your feet and follow any other foot care advice provided by your healthcare professional.
Glucose in urine
Due to how dapagliflozin works, your urine will test positive for glucose while taking this medication.
Children and adolescents
Dapagliflozin can be used in children aged 10 years or older for the treatment of type 2 diabetes. There is no data available in children under 10 years of age.
This medication is not recommended in children or adolescents under 18 years of age for the treatment of heart failure or for the treatment of chronic kidney disease, as it has not been studied in these patients.
Other medications and Zedilarf
Tell your doctor, pharmacist, or nurse if you are taking, have recently taken, or might take any other medications.
Especially inform your doctor:
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
You should stop taking this medication if you become pregnant, as its use is not recommended during the second and third trimesters of pregnancy. Consult your doctor about the best way to control blood sugar levels during pregnancy.
Consult your doctor if you want to breastfeed or are breastfeeding before taking this medication. Do not use dapagliflozina during breastfeeding. It is unknown whether this medication passes into human breast milk.
Driving and using machines
This medication has a negligible influence on the ability to drive or use machines.
Taking this medication with other medications called sulfonylureas or with insulin may cause low blood sugar levels (hypoglycemia), which can cause symptoms such as trembling, sweating, and vision changes that can affect your ability to drive or use machines.
Do not drive or use tools or machines if you feel dizzy while taking dapagliflozin.
Zedilarf contains lactose
Zedilarf contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Follow the instructions for administration of this medication indicated by your doctor. In case of doubt, consult your doctor, pharmacist, or nurse again.
What dose should you take
How to take this medication
Your doctor may prescribe dapagliflozin along with another medication(s). Remember to take these other medication(s) following your doctor's instructions. This will help you get the best results for your health.
Diet and exercise can help your body use blood sugar better. If you have diabetes, it is essential that you follow any diet and exercise program recommended by your doctor while taking dapagliflozin.
If you take more Zedilarf than you should
If you take more dapagliflozin tablets than you should, consult your doctor or go to the hospital immediately. Bring the medication package with you.
In case of overdose or accidental ingestion, consult your doctor or pharmacist or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Zedilarf
What you should do if you forget to take a tablet depends on how much time is left until your next dose.
If you stop taking Zedilarf
Do not stop taking dapagliflozin without consulting your doctor first. If you have diabetes, your blood sugar levels may increase without this medication.
If you have any further questions about the use of this medication, ask your doctor, pharmacist, or nurse.
Like all medications, this medication can cause side effects, although not everyone gets them.
Contact a doctor or the nearest hospital immediately if you experience any of the following side effects:
These are the signs of angioedema:
These are the signs of diabetic ketoacidosis (see also section 2 Warnings and precautions):
This can occur regardless of blood sugar levels. Your doctor should decide whether to temporarily or permanently stop your treatment with dapagliflozin.
Stop taking Zedilarf and consult a doctor immediately if you notice any of these serious side effects:
These are the signs of a serious urinary tract infection:
Although not very common, if you notice blood in your urine, inform your doctor immediately.
Contact your doctor as soon as possible if you experience any of the following side effects:
These are the signs of low blood sugar levels:
Your doctor will explain how to treat low blood sugar levels and what to do if you experience any of the above signs.
Other side effects of treatment with Zedilarf:
Common
Uncommon (may affect up to 1 in 100 people)
Rare
Reporting side effects
If you experience any side effects, consult your doctor, pharmacist, or nurse, even if they are not listed in this summary. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date stated on the blister or carton after "EXP". The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medications should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medication. In case of doubt, ask your pharmacist how to dispose of the packaging and any unused medication at the SIGRE point in the pharmacy. This will help protect the environment.
Zedilarf Composition
Each film-coated tablet (tablet) of Zedilarf 5 mg contains dapagliflozina propanediol monohydrate equivalent to 5 mg of dapagliflozin.
Each film-coated tablet (tablet) of Zedilarf 10 mg contains dapagliflozina propanediol monohydrate equivalent to 10 mg of dapagliflozin.
Product Appearance and Container Content
The film-coated tablets of Zedilarf 5 mg are yellow, biconvex, round tablets with a diameter of approximately 7.2 mm, film-coated, with "5" engraved on one side and flat on the other.
The film-coated tablets of Zedilarf 10 mg are yellow, biconvex, oval tablets with a size of approximately 11.1 mm x 6.1 mm, film-coated, with "10" engraved on one side and flat on the other.
Zedilarf tablets are available in OPA/Al/PVC//Al blisters in pack sizes of 10, 28, 30, 60, 90 or 98 film-coated tablets in non-perforated blisters; 14, 28, 56 or 98 film-coated tablets in non-perforated calendar blisters and in packs of 10x1, 28x1, 30x1, 50x1, 90x1, 98x1 or 100x1 film-coated tablets in perforated unit-dose blisters.
Only some pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
PharmaPath S.A.
28is Oktovriou 1,
Agia Varvara, 123 51,
Greece
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
Hungary Zedilarf 5 mg & 10 mg filmtabletta
Spain Zedilarf 5 mg film-coated tablets EFG
Zedilarf 10 mg film-coated tablets EFG
Poland Zedilarf
Date of the last revision of thisleaflet: August 2024
Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for ZEDILARF 5 mg FILM-COATED TABLETS – subject to medical assessment and local rules.